Johnson & Johnson
Global healthcare conglomerate with pharmaceutical, medical device, and consumer product divisions
What the page says before deeper research
Quality, growth, value, ownership, risk, and source confidence.
Moat 9.2/100 with low retention risk and high switching costs.
Growth appears mixed from +7.9% YoY revenue growth.
Forward P/E of 19.0x versus +7.9% growth gives a 2.4x multiple-to-growth read.
No SEC-backed 13F layer is matched yet, so ownership confirmation is unavailable.
Retention and AI disruption risks are low; valuation is not flagged expensive.
Fundamentals from finnhub as of 2026-05-17; ownership confirmation is not available here.
This is the cleanest available operating read on whether JNJ's healthcare engines are still expanding.
Beginner valuation check
Data pending from FMP or Finnhub.
Positive price performance shows recent market sentiment, not a full investment thesis.
Forward P/E around 19.0x means investors pay about $19.0 for each expected $1 of future profit per share, usually the next 12 months or next fiscal year. It is a forecast, not a fact.
A P/E around 25.9x means investors pay about $25.9 for each $1 the company earned per share over the last 12 months, usually the last four quarterly reports.
Source: market data index. As of May 21, 2026. P/E can be unavailable or misleading when earnings are negative.
Beginner guide
Johnson & Johnson makes medicines that help sick people get better and band-aids and baby shampoo that families use at home.
Global healthcare conglomerate with pharmaceutical, medical device, and consumer product divisions
Johnson & Johnson makes money through Innovative Medicine (~55% of revenue) and MedTech (~45% of revenue).
Regulatory moats through decades of clinical trial data and FDA relationships create 10-15 year competitive advantages
Johnson & Johnson can disappoint if execution, competition, valuation, or demand cycles weaken growth, margins, customer retention, or investor confidence.
Johnson & Johnson is like part of the healthcare toolkit: patients, providers, or researchers rely on it when quality and trust matter.
You are basically betting that Johnson & Johnson can keep turning innovative medicine into durable value while managing execution, competition, valuation, or demand cycles.
A 0-100 shortcut for how defensible the business looks in this company brief. Johnson & Johnson is scored at 9.2.
How painful it is for customers to leave. this company brief rates Johnson & Johnson as high.
Whether existing customers tend to spend more or less over time. The company brief model uses 118%.
The main pieces of the company here are Innovative Medicine and MedTech.
Price divided by earnings. It is a quick valuation check, but it can mislead when earnings are temporarily high, low, or negative.
A quarterly filing that shows what many large institutional investors owned at quarter end.
The first four questions
Johnson & Johnson's regulatory moat in Innovative Medicine can support durable growth if its pharma pipeline and MedTech execution keep converting clinical scale into revenue.
JNJ can disappoint if competition, execution, or demand cycles slow growth in Innovative Medicine or MedTech, especially if investors decide the current valuation leaves less room for error.
Forward P/E (19.0x)
Next earnings date unavailable from configured sources.
Bull / Neutral / Bear
JNJ continues as a large, defensive healthcare compounder, with the market focusing on whether the business can justify a forward multiple around 19.0x.
Forward P/E remains near 19.0x while revenue growth stays positive.
Innovative Medicine keeps benefiting from high switching costs, regulatory barriers, and long product lifecycles while MedTech continues to add steady growth.
Revenue growth stays near or above the current +7.9% pace.
JNJ continues as a large, defensive healthcare compounder, with the market focusing on whether the business can justify a forward multiple around 19.0x.
Forward P/E remains near 19.0x while revenue growth stays positive.
Slower execution or pressure in either Innovative Medicine or MedTech makes it harder for the company to support its current market setup.
Revenue growth cools, or business-specific momentum weakens in the core operating lines.
Beginner checklist
Needs earnings calendar data from a provider.
This is the cleanest available operating read on whether JNJ's healthcare engines are still expanding.
Margin trend needs company financial statement data; do not infer it from price movement.
Forward P/E is the main valuation anchor currently available for JNJ.
No SEC-backed ownership rows are available for this ticker yet.
Needs insider transaction data from a provider.
For JNJ, the key operating engine to watch is whether Innovative Medicine continues to offset slower areas elsewhere.
Johnson & Johnson is exposure to healthcare operating model with high switching costs and 118% net revenue retention.
Regulatory moats through decades of clinical trial data and FDA relationships create 10-15 year competitive advantages
The main question is whether the company can keep customer value compounding without margin pressure eroding the moat.
Pro access unlocks the workflow simulator for this company brief.
Simulator coverage pending
This ticker has a company brief, but richer workflow modules have not been built yet.
No SEC-backed 13F rows are matched for this ticker yet. We do not fabricate ownership rows.
- Regulatory moats through decades of clinical trial data and FDA relationships create 10-15 year competitive advantages
- Patient switching costs extremely high due to immunogenicity risks and established efficacy on current therapy
- Physician inertia reinforced by complex reimbursement processes and prior authorization requirements
- Manufacturing complexity (biologics, CAR-T) creates supply chain barriers competitors cannot easily replicate
- AI enhances drug discovery but cannot replicate regulatory approval timelines or safety databases